Everything Old Is New Again! Neoadjuvant Chemotherapy in the Treatment of Muscle-Invasive Bladder Cancer
Menés sur 39 et 44 patients atteints d'un cancer urothélial invasif, ces deux essais évaluent l'efficacité et la toxicité d'un traitement néoadjuvant à base de méthotrexate, vinblastine et cisplatine pour le premier, et à base de méthotrexate, vinblastine, doxorubicine et cisplatine pour le second
In the last decade, the range of therapeutic options for patients with various malignancies has expanded tremendously, driven primarily by advances in molecular biology and genomic medicine. However, treatments for patients with bladder cancer have changed little in the past two decades. The regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) was first described in 1985, and its use in the neoadjuvant setting was first reported in 1988...
Journal of Clinical Oncology , éditorial en libre accès, 2014